Chimeric antigen and T cell receptors and methods of use
AssigneeKite Pharma, Inc.
InventorsArianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
Life of this patent
Estimating the term…
Loading patent…
AssigneeKite Pharma, Inc.
InventorsArianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
Estimating the term…
Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
A polynucleotide encoding an anti-CD20 chimeric antigen receptor (CAR) comprising an anti-CD20 antigen-binding fragment, wherein the anti-CD20 antigen-binding fragment comprises a heavy chain variable domain (VH) comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable domain (VL) comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, respectively, comprise the amino acid sequences of SEQ ID NO:48, 51, 54, 59, 62 and 65.
A polynucleotide encoding an anti-CD20 chimeric antigen receptor (CAR) comprising an anti-CD20 antigen-binding fragment, wherein the anti-CD20 antigen-binding fragment comprises a heavy chain variable domain (VH) comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable domain (VL) comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, respectively, comprise the amino acid sequences of SEQ ID NO:70, 73, 76, 81, 84, and 87.
Dependencies are inferred from the claim text.